Margaret Shipp

Q: What Schools Are Affiliated With Margaret Shipp

Margaret Shipp is affiliated with the following schools: University of Texas Medical Branch, University of Buenos Aires, Stanford University, Humanitas University, Oregon Health & Science University, University of Bologna, Harvard University

Margaret Shipp's AcademicInfluence.com Rankings

Margaret Shipp

Philosophy

#7810

World Rank

#11068

Historical Rank

Logic

#4846

World Rank

#6175

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Margaret Shipp's Degrees

Doctorate Medicine Harvard University

Why Is Margaret Shipp Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Margaret Ann Shipp is an American hematologic oncologist. She is the Douglas S. Miller Chair in Hodgkin Lymphoma at Harvard Medical School. Shipp is an elected Fellow of the American Society for Clinical Investigation and National Academy of Medicine.

(See a Problem?)

Margaret Shipp's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A predictive model for aggressive non-Hodgkin's lymphoma. (1993) (4400)
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. (1999) (3170)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. (2015) (3005)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning (2002) (2443)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. (2010) (1068)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (974)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing (2012) (932)
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. (2003) (838)
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. (2004) (822)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016) (800)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. (2010) (778)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. (2017) (744)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. (2016) (729)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies (2013) (672)
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. (2013) (617)
Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. (1994) (559)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy (2012) (559)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. (2016) (558)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. (2016) (514)
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. (2007) (504)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018) (462)
Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors (2014) (411)
Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. (2012) (407)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. (2002) (384)
Targetable genetic features of primary testicular and primary central nervous system lymphomas. (2014) (382)
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma (2006) (374)
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. (2008) (317)
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007) (313)
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. (2017) (298)
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? (1994) (290)
The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo (2015) (286)
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. (1986) (274)
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. (2005) (261)
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas (2012) (244)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. (2007) (240)
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. (2017) (229)
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. (2018) (227)
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. (2017) (226)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (213)
Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! (1993) (211)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. (2019) (207)
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. (2005) (203)
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087. (2019) (201)
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. (1991) (198)
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. (1989) (194)
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. (2012) (190)
International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. (1999) (180)
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma (2012) (175)
NLRC5/MHC class I transactivator is a target for immune evasion in cancer (2016) (170)
CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. (1991) (168)
Downregulation of enkephalin-mediated inflammatory responses by CDl0/neutral endopeptidase 24.11 (1990) (165)
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. (1999) (164)
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. (2013) (163)
PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013) (2014) (157)
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. (1988) (155)
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. (2005) (154)
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. (2013) (153)
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. (1995) (150)
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. (1991) (150)
Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas (2012) (149)
B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity* (2005) (149)
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (2019) (147)
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. (2007) (142)
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas (2007) (140)
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. (2019) (136)
BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. (2009) (136)
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status (2016) (135)
Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) (2006) (134)
Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies (2014) (134)
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. (2000) (132)
Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain (2014) (131)
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. (1990) (130)
Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. (1993) (130)
Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity (2004) (129)
Interaction of immunoactive monokines (interleukin 1 and tumor necrosis factor) in the bivalve mollusc Mytilus edulis. (1990) (127)
Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. (1989) (122)
The BAL-binding Protein BBAP and Related Deltex Family Members Exhibit Ubiquitin-Protein Isopeptide Ligase Activity* (2003) (122)
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. (2003) (118)
Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo (2014) (118)
BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate (2006) (114)
A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039) (2016) (113)
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. (2016) (110)
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. (1997) (109)
Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study (2016) (104)
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. (2018) (104)
Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. (1996) (103)
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. (2006) (99)
The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. (1987) (95)
CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. (1992) (91)
Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. (1993) (91)
BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8 (2012) (89)
Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. (1995) (88)
PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. (1999) (82)
Expression of bcl-6 and CD10 in Primary Mediastinal Large B-Cell Lymphoma: Evidence for Derivation From Germinal Center B Cells? (2001) (81)
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. (2019) (79)
CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. (1993) (76)
Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. (2012) (76)
Seventy-Two Hour Continuous Infusion Flavopiridol in Relapsed and Refractory Mantle Cell Lymphoma (2002) (75)
Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. (2011) (75)
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. (2019) (74)
Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma (2007) (74)
The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. (2000) (73)
AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features (2008) (72)
Identification and characterization of two androgen response regions in the human neutral endopeptidase gene (2000) (71)
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039) (2015) (70)
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. (2018) (69)
Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. (1985) (66)
Molecular Diagnostics (2023) (65)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome (2015) (64)
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma (2020) (63)
BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. (2008) (62)
Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism* (1998) (62)
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. (2016) (60)
Stromelysin‐3 suppresses tumor cell apoptosis in a murine model * (2001) (58)
CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. (1994) (58)
Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. (2019) (56)
Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes (2017) (55)
Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program (2011) (55)
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. (2018) (54)
Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets (2016) (54)
TRAF1 Expression and c-Rel Activation Are Useful Adjuncts in Distinguishing Classical Hodgkin Lymphoma From a Subset of Morphologically or Immunophenotypically Similar Lymphomas (2005) (54)
Mass cytometry of Hodgkin lymphoma reveals a CD 4 + exhausted T-effector and T-regulatory cell rich microenvironment (2018) (53)
FAS Death Domain Deletions and Cellular FADD-like Interleukin 1β Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes (2006) (53)
Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. (1989) (53)
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. (2016) (53)
Prognostic factors in non-Hodgkin's lymphoma. (1992) (51)
A possible immunoregulatory function for [Met]-enkephalin-Arg6-Phe7 involving human and invertebrate granulocytes (1991) (50)
in diff use large B cell lymphoma (2006) (49)
Differential expression of nuclear proto-oncogenes in T cells triggered with mitogenic and nonmitogenic T3 and T11 activation signals. (1987) (48)
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. (2017) (48)
Chemotherapy of non-Hodgkin's aggressive lymphomas. (1994) (48)
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study (2016) (47)
CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. (1992) (47)
The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27). (1989) (46)
The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. (1997) (46)
Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma (2016) (43)
Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. (1995) (43)
CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. (1996) (42)
Report of the first workshop on prognostic factors in large-cell lymphomas. (1991) (40)
PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment (2015) (39)
MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1 (2010) (39)
Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas (2008) (38)
Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site. (1992) (37)
Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo. (1993) (35)
Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer (2005) (34)
The heat shock protein 90 inhibitor IPI‐504 induces apoptosis of AKT‐dependent diffuse large B‐cell lymphomas (2009) (33)
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. (2018) (33)
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. (2015) (32)
FBXO 11 targets BCL 6 for degradation and is inactivated in diffuse large B-cell lymphomas (2011) (31)
Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL) (2008) (31)
Can we improve upon the International Index? (1997) (31)
Opioid receptor agonists and Ca2+ modulation in human B cell lines. (1992) (30)
High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma. (1984) (30)
A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. (1998) (30)
Inactivation of the PRDM 1 / BLIMP 1 gene in diff use large B cell lymphoma (2006) (29)
Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study (2016) (29)
Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma (2018) (25)
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. (2016) (24)
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas (2010) (23)
Active stromelysin‐3 (MMP‐11) increases MCF‐7 survival in three‐dimensional Matrigel culture via activation of p42/p44 MAP‐kinase (2003) (22)
Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study (2014) (20)
Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma. (2006) (19)
Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These Tumor Types From Morphologically and Phenotypically Similar Lymphomas (2011) (19)
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas (2019) (19)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia (2016) (18)
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial (2017) (18)
Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma. (2020) (18)
NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL (2017) (18)
Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies (2018) (18)
A unique DR-related B cell differentiation antigen. (1983) (18)
Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. (1988) (17)
Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL) (2015) (17)
Drug‐related pulmonary toxicity in non‐Hodgkin's lymphoma. Comparative results with three different treatment regimens (1991) (17)
A roadmap for discovery and translation in lymphoma. (2015) (17)
Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study. (2016) (16)
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (15)
Molecular signatures define new rational treatment targets in large B-cell lymphomas. (2007) (15)
Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias. (1996) (15)
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. (2017) (14)
Tumor Cell-mediated Induction of the Stromal Factor Stromelysin-3 Requires Heterotypic Cell Contact-dependent Activation of Specific Protein Kinase C Isoforms* (2005) (14)
PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY (2017) (14)
Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial (2017) (14)
GLEPP1/Protein-tyrosine Phosphatase ϕ Inhibitors Block Chemotaxis in Vitro and in Vivo and Improve Murine Ulcerative Colitis (2009) (14)
NCCN preliminary non-Hodgkin's lymphoma practice guidelines. (1997) (14)
Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(1)(q22) and t(1;7)(q21;q11) (1988) (13)
Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study (2018) (13)
Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study (2018) (13)
Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma (2018) (12)
No Evidence for the JAK2 (V617F) or JAK2 Exon 12 Mutations in Primary Mediastinal Large B-cell Lymphoma (2009) (12)
Moving Towards a Molecularly Targeted Approach (2005) (12)
Relationship to Cellular Proliferation (1994) (12)
The cellular and molecular heterogeneity of the aggressive non‐Hodgkin's lymphomas (1998) (12)
Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial (2016) (12)
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY (2021) (11)
Inflammatory effector mechanisms in asthma. (1995) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (2020) (9)
nivolumab In Patients With Relapsed Or Refractory Lymphoid Malignancies And Classical Hodgkin Lymphoma: Updated Results Of A Phase 1 Study (ca209-039) : 010 (2015) (8)
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis (2020) (8)
PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL (2017) (8)
Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) (2021) (8)
lymphoma sclerosing Hodgkin lymphoma and primary mediastinal large B-cell PD-1 ligand expression, and further induction via JAK2 in nodular Integrative analysis reveals selective 9p24.1 amplification, increased (2010) (7)
CD 10 (CALLA, common acute lymphoblastic leukemia antigen)/neutral endopeptidase 24.11 (NEP, “nkephalinase”) : molecular structure and role in regulating met-enkephalin mediated inflammatory responses (1991) (7)
Human Cancer Biology PD-L 1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies (2013) (7)
Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade) (2016) (6)
B-Aggressive Lymphoma (BAL) Family Proteins Have Unique Domains Which Modulate Transcription and Exhibit PARP Activity. (2005) (6)
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D. (2016) (6)
A Directly Spliced Exon 10–Containing CD44 Variant Promotes the Metastasis and Homotypic Aggregation of Aggressive Non-Hodgkin's Lymphoma (1998) (5)
2. Report on the Workshop: “Clinical Consequences of Pathology and Prognostic Factors in Aggressive NHL” (2001) (5)
CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA (2017) (5)
HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) (2021) (5)
A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL). (2005) (5)
A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (2017) (5)
Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass. (2005) (5)
Validation of the Genetically-Defined DLBCL Subtypes and Generation of a Parsimonious Probabilistic Classifier (2019) (5)
Comprehensive Genomic Analysis of Primary Mediastinal B-Cell Lymphoma (2018) (4)
CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN (2016) (4)
Quantitative Assessment of PD-L1 Expression in Classical Hodgkin Lymphoma Suggests a Critical Role for Tumor Associated Macrophages in Suppressing Anti-Tumor Immunity (2015) (4)
Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma (2016) (4)
Non-small Cell Lung Carcinomas (4)
In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas (2016) (4)
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop (2016) (3)
Expression and Targeted Inhibition of the Immunoregulatory Carbohydrate-Binding Lectin, Galectin 1, in EBV-Driven Post-Transplant Lymphoproliferative Disorders. (2009) (3)
Tonic B-Cell Receptor Signaling Promotes the Survival of Diffuse Large B-Cell Lymphomas: Identification of SYK as a Rational Treatment Target. (2006) (3)
Multicohort phase 2 study of pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R Chl): Keynote-087. (2016) (3)
An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 (2015) (3)
High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351 (2007) (3)
The Mutational Landscape of Diffuse Large B Cell Lymphoma (2011) (3)
Molecular Diagnostics (2003) (2)
AP 1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with SharedMolecular Features (2008) (2)
Molecular proﬁling of diffuse large B-cell lymphoma identiﬁes robust subtypes including one characterized by host inﬂammatory response (2005) (2)
Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (2018) (2)
Rational Therapeutic Targets in Large B-Cell and Mantle Cell Lymphomas (2007) (2)
T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development (2016) (2)
Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11) (1988) (2)
The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA (2014) (2)
A new polymorphic determinant on HLA-DQ molecules. (1986) (2)
Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion (2018) (2)
New concepts in treatment approaches and prognostic factors in aggressive NHL. (2006) (2)
Lymphomas and Virus-Associated Malignancies PD-L 1 Expression Is Characteristic of a Subset of Aggressive B-cell (2013) (2)
CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma (2013) (2)
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (1)
PROTEIN TYROSINE PHOSPHATASE RECEPTOR-TYPE O TRUNCATED (PTPROt) REGULATES SYK PHOSPHORYLATION, PROXIMAL B-CELL RECEPTOR SIGNALING AND CELLULAR PROLIFERATION Running title: PTPROt regulates SYK activity and BCR signaling (2016) (1)
Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation (2022) (1)
Hodgkin’s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape. (2006) (1)
target in diffuse large B-cell lymphoma SYK-dependent tonic B-cell receptor signaling is a rational treatment (2013) (1)
FusionQuery: a novel tool for gene-specific fusion detection (2014) (1)
BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted. (2006) (1)
Heat Shock Protein 90 (HSP90) Is a Rational Therapeutic Target in Diffuse Large B-Cell Lymphoma. (2006) (1)
Mir-15a/16-1 Cluster Is Frequently Deleted In Primary Hodgkin Lymphoma and Modulates Multiple Survival Pathways Including AP-1 (2010) (1)
Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma (2013) (1)
Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma (2013) (1)
GIANNI BONADONNA MEMORIAL LECTURE: “GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES” (2017) (1)
Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study (2020) (1)
Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 (2015) (1)
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation (2018) (1)
The BBAP E3 Ligase Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response in Chemotherapy-Resistant Lymphomas. (2009) (1)
Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome (2017) (1)
Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study (2016) (1)
49TiPKEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS) (2016) (1)
FAS Death Domain Deletions and Increased c-FLIPlong Expression Occur in Different Subtypes of Diffuse Large B-Cell Lymphoma. (2005) (1)
Novel Epigenetic Vulnerabilities for Diffuse Large B-Cell Lymphoma (2018) (1)
Abstract 3547: Disruption of Galectin1-glycan interaction impairs tumor growth and metastasis in breast cancer by disarming the immunosuppressive capacity of regulatory T cells (2012) (0)
with classical Hodgkin lymphoma from that of other diffuse large B-cell lymphomas and shares features The molecular signature of mediastinal large B-cell lymphoma differs (2013) (0)
B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, γIFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response. (2004) (0)
Abstract A38: Cd70 genetic perturbation limits the development of an effective CD8+ T-cell immune response to Bcl6-driven diffuse large B-cell lymphoma (2022) (0)
HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION IN AGGRESSIVE NON-HODGKIN'S LYMPHOMA. AUTHOR'S REPLY (1999) (0)
Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL) (2021) (0)
Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064. (2017) (0)
Can aggressive lymphomas be grouped for treatment (1999) (0)
Reply to Z. Wu et al. (2018) (0)
Antigene de la leucemie lymphoblastique aigue commune (1988) (0)
Integrative Analysis Reveals Multiple Alterations of p53 Signaling Pathway Components In Primary Diffuse Large B-Cell Lymphomas (2010) (0)
DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites. (2023) (0)
PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma The phosphodiesterase PDE4B limits cAMP-associated (2011) (0)
NFκB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFκB Target Genes. (2004) (0)
Identification of a sulfate-bearing i class II antigens (major histocompatibility complex/Ia antigens/proteoglycan) (2016) (0)
T028: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade (2022) (0)
Insights Into Pathophysiology of Lymphomas Help Identify Therapeutic Targets (2014) (0)
Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma (2021) (0)
Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements (2008) (0)
B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development (2015) (0)
Aberrant Ras Activation Associated with Functional Loss of Tnk1/Kos1 In Human B-Cell Lymphoma (2010) (0)
Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL (2018) (0)
Inactivation of the PRDM1/BLIMP1 Gene in Non-GC-Type Diffuse Large B-Cell Lymphoma. (2005) (0)
Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade (2019) (0)
Molecular characterization of a novel gene, bal, which regulates the proliferation of aggressive B-cell lymphomas (1997) (0)
Molecular profiling of diffuse large B-cell lymphoma reveals discrete clusters including one characterized by host inflammatory response (2004) (0)
HMS Task Force on Faculty Development and Diversity (2010) (0)
Abstract 5582: A targeted molecular classifier of MYC activity and BCL-2 expression in aggressive B-cell lymphomas, designed for clinical practice (2014) (0)
T026: CHARACTERIZATION OF CANCER-ASSOCIATED FIBRO- BLASTS IN CLASSICAL HODGKIN LYMPHOMA (2022) (0)
The Genetic Substructure of Diffuse Large B-cell Lymphoma: Implications for Diagnosis, Prognosis and Therapy (2019) (0)
Abstract A37: The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA. (2015) (0)
Abstract 5675: Single-cell mass cytometry of classical Hodgkin lymphoma defines an exhausted and immunosuppressive microenvironment (2018) (0)
Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma (2015) (0)
Abstract IA38: Identification of targetable vulnerabilities in lymphoma. (2015) (0)
A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma (2012) (0)
MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8 (2021) (0)
Inhibition of CD 10 / neutral endopeptidase 24 . 11 promotes B-cell reconstitution and maturation in vivo ( common acute lymphoblastic leukemia antigen / lymphoid progenitors / differentiation / cell surface enzyme ) (2005) (0)
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
Signatures of Response to the Proteasome Inhibitor Bortezomib in Diffuse Large B-Cell Lymphoma. (2005) (0)
Abstract IA6: Immune escape mechanisms in lymphoid malignancies. (2013) (0)
A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma. (2006) (0)
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. (2022) (0)
The b-lymphoid protein tyrosine phosphatase ptprot modulates b-cell activation following bcr engagement (2000) (0)
Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies. (2005) (0)
A Clinical Perspective: The Use of Prognostic Factors to Identify High-risk Patients Requiring Risk-adjusted Therapy (1996) (0)
lymphoproliferative disorders post-transplant + Viral induction and targeted inhibition of galectin-1 in EBV (2011) (0)
Gastric MALT Lymphoma: A Cooperative Pathological, Molecular and Clinical Approach (2009) (0)
Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy (2015) (0)
Clinical and biological prognostic factors in diffuse large B cell lymphoma (1999) (0)
Mediastinal Large B-Cell Lymphoma : A unique subset of diffuse large B-cell lymphoma with an expression signature resembling that of Hodgkin ’ s Reed-Sternberg Cells (2004) (0)
Biomarkers for immune checkpoint blockers (2018) (0)
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170. (2023) (0)
Learn About the Best From the Best at the 2013 Highlights of ASH ® (0)
Detecting Apoptotic Blocks and Sensitvity to ABT-737 and Conventional Chemotherapy Via BH3 Profiling. (2007) (0)
3090 – KDM4A/C SUSTAIN AN ONCOGENIC PROGRAM BY EPIGENETIC REWIRING OF ONCOGENIC AND LINEAGE ENHANCERS (2020) (0)
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
Report o f a n I nternational W orkshop t o S tandardize Response C riteria f or N on-Hodgkin's L ymphomas (1999) (0)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (2018) (0)
Molecular cloning ofthecommonacutelymphoblastic leukemia antigen (CALLA)identifies atypeIIintegral membraneprotein (1988) (0)
Abstract 4027: Recurrent gains of CD274 (PD-L1) and PDCD1LG2 (PD-L2) provide a genetic basis for PD-1 ligand expression in a subset of solid tumors (2016) (0)

This paper list is powered by the following services:

Other Resources About Margaret Shipp

en.wikipedia.org

What Schools Are Affiliated With Margaret Shipp?

Margaret Shipp is affiliated with the following schools:

Margaret Shipp's Academic­Influence.com Rankings